In pediatric radiotherapy, what clinicians can see during treatment can shape the decisions they make in the room. Pediatric cancer presents unique challenges. Children's bodies are still developing, and while treating the tumor effectively is essential, protecting healthy tissues is equally important. Every millimeter matters. Every treatment decision can influence not only survival, but also long-term quality of life.
","regulatory":false},{"id":3074,"name":"First patient in Japan treated with Elekta Evo marks a step toward more personalized radiotherapy","url":"https://ir.elekta.com/investors/newsroom/2026/first-patient-in-japan-treated-with-elekta-evo-marks-a-step-toward-more-personalized-radiotherapy/","date":"2026-10-01T08:00:00.000Z","intro":"The first patient in Japan has been treated with Elekta Evo at Hyogo Medical University Hospital, marking the system’s first clinical use in the country.
","regulatory":false},{"id":3072,"name":"New phase 2 data show favorable cognitive outcomes with Leksell Gamma Knife in patients with up to 50 brain metastases","url":"https://ir.elekta.com/investors/press-releases/2026/new-phase-2-data-show-favorable-cognitive-outcomes-with-leksell-gamma-knife-in-patients-with-up-to-50-brain-metastases/","date":"2026-09-29T19:00:00.000Z","intro":"BOSTON – Elekta (EKTA-B.ST) today announced new phase 2 data, presented at ASTRO by lead investigator Dr. Chia-Lin Tseng, demonstrating favorable cognitive outcomes with Leksell Gamma Knife® radiosurgery in patients with up to 50 brain metastases. The study, conducted by researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, evaluated focal stereotactic radiosurgery in patients with 5 to 50 brain metastases. The findings support a growing body of evidence that Gamma Knife radiosurgery may expand the use of focal treatment to patients with a higher number of brain metastases than traditionally considered.
","regulatory":false},{"id":3068,"name":"Study presented at ASTRO shows promising long-term outcomes for patients with localized pancreatic cancer treated on Elekta Unity","url":"https://ir.elekta.com/investors/press-releases/2026/study-presented-at-astro-shows-promising-long-term-outcomes-for-patients-with-localized-pancreatic-cancer-treated-on-elekta-unity/","date":"2026-09-28T17:00:00.000Z","intro":"New data underscore the potential of MR-guided adaptive radiotherapy as Elekta advances Elekta Unity with Unity Pro to help bring adaptive treatment to more centers.
","regulatory":false},{"id":3062,"name":"Elekta expands adaptive workflows across its radiotherapy portfolio","url":"https://ir.elekta.com/investors/press-releases/2026/elekta-expands-adaptive-workflows-across-its-radiotherapy-portfolio/","date":"2026-09-27T15:40:00.000Z","intro":"New capabilities across CT, MR, radiosurgery and brachytherapy give centers more ways to bring adaptive treatment into everyday clinical practice.
","regulatory":false}]